Go to Home page Go to Home page
Logo Highlight Therapeutics 60 aniversario
Explora
(506) 2437-2200
Lunes - Viernes 9am - 5pm (GMT-6)
O solicita más información con nuestro formulario de contacto
Research & Innovation
Portal
Press release
News
10 de junio de 2024
Call for general ordinary shareholders’ meeting of the company highlight therapeutics, S.L.
June 26th, 2024, at 11:00
Investors
4 de octubre de 2023
Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L.
October 20th, 2023, at 11:30
Investors
7 de junio de 2023
Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L.
June 26, 2023, at 11:30
Investors
1 de junio de 2022
Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L.
June 27, 2022, at 12:30
Investors
13 de abril de 2022
Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
Press Release
15 de marzo de 2022
Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
Press Release
2 de diciembre de 2021
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Press Release
12 de noviembre de 2021
Highlight announces positive preliminary results from Phase 2b study of BO-112+anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC
Press Release
15 de abril de 2021
Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L.
April 30th, 2021, at 11:00
Investors
14 de abril de 2021
Highlight to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data
Press Release
2 de marzo de 2021
Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety
Press Release
15 de septiembre de 2020
Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L.
October 1, 2020, at 11:00
Investors
2 de septiembre de 2020
Second collaboration with MSD to evaluate combination of BO-112 and KEYTRUDA®
Press Release
26 de junio de 2020
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis
Press Release
9 de junio de 2020
Call for general ordinary shareholders’ meeting of the company highlight therapeutics, S.L.
June 25, 2020, at 12:00
Investors
17 de abril de 2020
Highlight Therapeutics strengthens Board and Advisory Board
Press Release
17 de abril de 2020
Highlight Therapeutics announces name change from Bioncotech and launch of new website
Press Release
17 de abril de 2020
Highlight Therapeutics commentary published in the European Biotechnology magazine
Press Release
2 de abril de 2020
Highlight Therapeutics published in the European Biopharmaceutical Review
Press Release
28 de febrero de 2020
Highlight Therapeutics selected for Cancer Research UK project
Press Release
12 de diciembre de 2019
Phase I BO-112 Data Presented at ESMO Immuno-Oncology Congress 2019
Press Release
10 de diciembre de 2019
Oncology Clinical Trial Collaboration with MSD
Press Release
Unlocking the potential of
dermato-oncology treatment
Contact us